Anthropometric assessments 165
Body weight was measured without shoes and in underwear to the nearest 100g using 166 electronic scales. Height without shoes was measured using a stadiometer. Waist-, 167 head-and hip-circumferences were measured using a non-stretch tape. All measures 168 were recorded in duplicate, or triplicate if the first 2 measures differed by >0.1kg 169 (weight) or >0.5cm (height/girths), and averaged for analysis. Weight and height 170 measurements were used to calculate BMI (weight in kg/height in metres 2 ). The 171 measures for each child were compared with standardized reference charts for the 172 child's age and sex to calculate their z-scores (15, 16) . Corrected ages were used for 173 children born preterm (<37 weeks' gestation). The number of children classified as 174 underweight (BMI<10 th percentile), overweight (BMI>85 th percentile) and obese 175 (BMI> 90 th percentile) was determined at each age. 176
Total fat and fat-free mass were assessed using Bioelectrical Impedance Spectroscopy 178 (BIS) (17) . Fat-free mass was derived from the measure of total body water using an 179 equation previously validated for use in paediatric populations (18, 19) . %BF was then 180 determined by subtracting the fat-free mass from the body weight, dividing by body 181 weight and multiplying by 100. 182 183 Systolic, diastolic and mean arterial blood pressure at 5 years of age were assessed in 184 duplicate using a DINAMAP Procare V100 monitor (GE Health Care) with an 185 appropriate sized cuff. 186
187

Blood sample collection and processing 188
Children were instructed to fast for at least 4 hours prior to their 5 year clinic 189 appointment and blood samples (~5ml) were collected into tubes treated with EDTA, 190 kept on ice until transfer to the laboratory and processed (centrifugation at 1,500 x g 191 for 30 minutes at 4°C) within 24 hours. The plasma and buffy coat fractions were 192 separated into aliquots and frozen at -80°C, and the red blood cells washed in sterile 193 saline, lipids extracted into chloroform and used to assess fatty acid composition of 194 the phospholipids as previously described (20) . 195
196
Determination of insulin sensitivity 197
Glucose and insulin concentrations in the 5 year plasma samples were determined 198 using an enzymatic assay (Thermo Electron, Pittsburgh, PA) and human 199 ultrasensitive insulin ELISA kit (ALPCO Diagnostics, Salem, NH) respectively. The 200 intra-and inter-assay coefficients of variation for both assays were <10%. 
Other measures 210
In the DOMInO trial, maternal weight, height and BMI, parity, education and 211 smoking status were collected at enrolment. Weight and height of the biological 212 mother of the child were re-measured by clinic staff at the time of the 5year 213 assessments. Questions on home environment, education and employment of the 214 primary carer and whether the participant had requested to be unblinded were also re-215 asked at the time of the 3 and 5 year assessments. 216
217
At both the 3 and 5 year follow-up, detailed information on care outside the home and 218 general health of the child was collected at the clinic appointment. Information on 219 feeding practices in the first 6-12 months, family food environment and the child's 220 habitual dietary intake, physical activity and screen time was collected using a 221 structured questionnaire completed by the primary carer. 222
223
Sample size and statistical analysis 224
Follow-up of the 1660 children born to women enrolled in Adelaide-based centers 225 would provide over 90% power to detect a 3% relative reduction in the mean BMI 226 (16kg/m 2 to 15.52kg/m 2 , standard deviation 1.6kg/m 2 ), and a 2% absolute reduction in 227 the mean %BF (25% to 23% at 3 years and 21% to 19% at 5 years, standard deviation 228 5%), in boys and girls separately, allowing for 10% loss to follow-up (alpha=0.05).
All analyses were performed on an intention-to-treat basis, according to the treatment 230 group allocated at randomization. Multiple imputation was performed separately by 231 treatment group using chained equations to create 100 complete datasets for analysis, 232 assuming that data were missing at random. The effect estimates from the imputed 233 datasets were combined using Rubin's rules (21). The primary analysis was based on 234 imputed data and included all participants who consented to the follow-up study. 235
Sensitivity analyses were performed on the available data and on imputed data for all 236 1660 children born to women enrolled in Adelaide-based centers. All analyses 237 produced similar results and only the results of the primary analysis are presented. 238
239
Continuous outcomes were analyzed using linear regression models, with treatment 240 effects expressed as differences in means. For continuous outcomes that were log 241 transformed prior to analysis, treatment effects are expressed as ratios of geometric 242 means on the original scale. Binary outcomes were analyzed using log binomial 243 regression models, with treatment effects expressed as relative risks (RRs). For 244 outcomes measured at both 3 and 5 years, the repeated measurements were taken into 245 account using generalized estimating equations, with treatment effects estimated at 246 each time point separately. A priori secondary analyses were performed to test for 247 effect measure modification by sex and PPARγ genotype. 248
249
Both unadjusted and adjusted analyses were performed, with adjustment for the 250 stratification variables, center and parity, as well as pre-specified variables 251 depending on the outcome that included the child's sex and PPARγ genotype and the 252 mother's secondary education, further education, smoking status and BMI at 253 enrolment. Statistical significance was assessed at the 2-sided P<0.05 level. Noadjustment was made for multiple comparisons and results of secondary analyses 255 should be interpreted with caution unless highly significant. 256 257 Post-randomization child demographics and clinical characteristics were compared 258 between treatment groups based on the available data using chi-square tests for 259 categorical variables, Mann-Whitney U tests for continuous variables and log Poisson 260 regression for count variables. All analyses followed a pre-specified statistical 261 analysis plan and were performed using SAS version 9.3 (Cary, NC, USA). 262
263
Results
264
Participant flow and baseline characteristics 265
Participant flow is shown in The sociodemographic characteristics of the families in the subset consenting to 274 follow-up were comparable between the treatment groups at baseline (Table 1 ) and at 275
The BMI z-scores of children in the DHA group did not differ from the control group 280 at either 3 years ( either sex or PPARγ genotype in relation to BMI z-score or %BF at 3 or 5 years of 287 age (data not shown).There was no difference in the proportion of children classified 288 as overweight or obese between the treatment groups at either 3 or 5 years ( Table 2) . 289
290
Other anthropometric outcomes 291
Bodyweight and height z-scores were similar between groups, as was the average 292 weight gain between 3 and 5 years of age ( Table 2) . Hip and waist circumferences 293 and waist circumference z-scores were also not different between the treatment 294 groups at either 3 or 5 years ( Table 2 ). The waist:hip ratio was slightly higher in the 295 DHA group compared to the control group at 3 years (adjusted mean difference, 0.00, 296 95% CI 0.00 to 0.01, P=.04), but was not different between groups at 5 years (P=.43). 297
Total and percentage fat-free mass, total body water and the impedance index was not 298 different between groups at either 3 or 5 years ( Table 2) . Head circumference, head 299 circumference z-score and the change in head circumference between 3 and 5 years 300
were also similar between groups (Table 2 ).
In both adjusted and unadjusted analyses, insulin resistance at 5 years of age, as 305 assessed by HOMA-IR, was higher in children in the DHA group compared to 306 controls ( Table 3 ;adjusted ratio of geometric means, 1.20, 95% CI 1.04 to 1.39, 307 P=.01). Fasting insulin levels were also higher in the DHA group (adjusted ratio of 308 geometric means, 1.17, 95% CI 1.03 to 1.33, P=.02). There was an interaction 309 between treatment group and sex for fasting glucose concentrations (P=.03), such that 310 boys in the DHA group had higher fasting glucose concentrations than boys in the 311 control group (adjusted mean difference 0.21, 95% CI 0.01 to 0.42, P=.04), however 312 there were no differences between groups in girls. Similar effects were observed 313 for both fasting insulin concentrations and HOMA-IR. Boys in the DHA group had 314 significantly higher mean HOMA-IR (adjusted ratio of geometric means 1.35, 95% CI 315 1.11 to 1.65, P=.003) and fasting insulin levels (adjusted ratio of geometric means 316 1.26, 95% CI 1.05 to 1.51, P=.01) compared with the control group, while no 317 differences were seen for girls, however, the interactions between treatment and 318 sex were not significant for HOMA-IR (P=.13) or fasting insulin (P=.28). All 319 results were independent of the PPARγ genotype of the child. 320
321
Other post-randomization variables 322
More families from the control group had requested to be un-blinded compared with 323 the DHA group at both the 3 and 5 year time-points, but these represented <10% of 324 the cohort. Maternal and paternal BMI at baseline and at the time of the 3 and 5 year 325 follow-up was also similar between groups (Supplementary Table 1) . 326 Table 2 ) or habitual dietary intake, family food environment or reported levels of 330 physical activity or screen time at either 3 or 5 years (Supplementary Table 3) . 331
Systolic, diastolic and mean arterial blood pressure and fatty acid composition of red 332 blood cell phospholipids at 5 years of age were also similar between groups 333
(Supplementary Table 4). 334 335
Discussion 336
The results of this study do not support the hypothesis that increasing maternal DHA 337 intake by 800mg/day during the second half of pregnancy can influence body weight, 338 BMI z-score or body fat mass of the children either positively or negatively. We 339 have many reasons to have a high degree of confidence in our findings. The DOMInO 340 trial is the largest RCT of DHA supplementation during pregnancy, and has high 341 retention and long-term follow-up rates of the children. It is also the first study to 342 include two measures of obesity/body fat mass, i.e. BIS and BMI z-score, at two ages 343 and to investigate the potential impact of child genotype on their response to the 344 prenatal DHA intervention. remains high at 5 years of age, despite the fact that this is considered to be a period of 352 increased physical activity and lower BMI/fat mass which precedes the adiposity
355
Our study suggests a possible negative effect of prenatal DHA supplementation on 356 waist:hip ratio and insulin sensitivity. An increased waist circumference has 357 previously been reported in children at 2.5 years whose mothers were supplemented 358 with DHA during lactation (5). While ours is the first study to determine the effect of 359 prenatal DHA supplementation on insulin sensitivity, our findings are unexpected 360
given existing data from in vitro and experimental animal studies suggesting that 361 DHA increases insulin sensitivity (25, 26) . While it is possible that the observed 362 differences in insulin sensitivity and waist:hip ratio may indicate a true underlying 363 adverse effect of DHA supplementation, these were secondary outcomes and as such 364 require confirmation. It is also important to note that the differences between groups 365 were small and that the measures in both groups fell within the normal range. 366
367
The PPARγ Pro12Ala SNP is present in ~20% of Caucasian populations and has been 368 consistently associated with a reduced risk of obesity and type 2 diabetes in 369 epidemiological studies (14, 27) . While there were no significant interactions between 370
PPARγ genotype and treatment in our study, we were likely underpowered to detect 371 such interaction effects, and further studies will be needed to explore possible 372
interactions. 373 374
In light of the fact that ~70% of pregnant women in Adelaide are now consuming 375 nutritional supplements which provide at least some DHA, it is encouraging that this 376 long-term follow-up of the DOMInO trial showed no detrimental effects of maternal 377 DHA supplementation on childhood growth or body composition. These data, 378 together with the absence of significant effects on development in this same studypopulation at 4 years (28) , support the safety of high-dose DHA supplements in 380 pregnancy for the long term health of the child. 381
382
Conclusion 383
The results of this follow-up study provide no evidence to support the hypothesis that 384 increasing maternal DHA intake during the second half of pregnancy influences body 385 weight, BMI or body fat mass of the children, at least up to 5 years of age. We cannot 386 extend our conclusion to suggest that maternal DHA intake does not influence later 387 fat deposition in the child, however, it seems that any effects on growth are likely 388 small, and are far outweighed by the influence of other factors, such as genetics and 389 environment, experienced by the child after birth. This trial therefore provides the 390 most robust data to date that maternal DHA supplementation during pregnancy is not 391 an effective strategy by which to reduce the population burden of childhood obesity. Data are presented as mean (SD) with effect being difference in means unless otherwise indicated. Analyses are based on 100 imputed datasets. a Data are presented as median (IQR) with effect being ratio of geometric means. b Adjusted for center, parity, maternal BMI at study entry, infant sex, mother's secondary education, mother's further education, mother's smoking status, PPARγ genotype.
